<img alt="" src="https://secure.lazy8krti.com/218831.png" style="display:none;">

Case study: How we helped maximise the uptake of biosimilars in an evolving market

The solution
Our client was developing biosimilars of two biologic drugs and wanted to understand the likely market potential for their assets.
We conducted a quantitative online survey, which included conjoint exercises, to identify the drivers for uptake amongst Dermatologists, Gastroenterologists and Rheumatologists. We also gauged the impact of the biosimilars on other treatments, including originator biologics and prelaunch products expected to impact the immunology market.

Biosimilars article
Biosimilars article

The solution
Our client was developing biosimilars of two biologic drugs and wanted to understand the likely market potential for their assets.
We conducted a quantitative online survey, which included conjoint exercises, to identify the drivers for uptake amongst Dermatologists, Gastroenterologists and Rheumatologists. We also gauged the impact of the biosimilars on other treatments, including originator biologics and prelaunch products expected to impact the immunology market.

The outputs
Using a Juster Scale to calibrate estimates of future behaviour, the findings provided out client with a clear view of the anticipated market share for biosimilars overall and for their particular assets. Our client was able to understand how their biosimilars, and potential competitors, would meet physician needs, and identify the key characteristics required for each physician audience. They were able to use this information to understand how to maximise uptake of their biosimilars across multiple disease areas and guide their future portfolio strategy.

Sign up to receive Rapport

Rapport is our e-newsletter and online resource for sharing our expertise and experience in global healthcare market research.

Sign up here